What is already known about this topic? Visceral leishmaniasis (VL) is an important vectorborne disease in rural areas of western China. The spreading of VL made its prevention and control become more complicated. What is added by this report?The number of VL cases decreased from 2015 (n=498) to 2019 (n=166). However, the mountain-type zoonotic visceral leishmaniasis (MT-ZVL) cases increased from 2015 (n=82, 16.5%) to 2019 (n=122, 73.5%). In addition, both number and proportion of imported cases increased from 2015 (n=18, 3.6%) to 2019 (n=41, 24.7%). The re-emergence of MT-ZVL was considerable; 13 historically-endemic counties reported 48 indigenous cases. Infants and young children were the high risk population of VL (848, 62.4%) followed by farmers (303, 22.3%). What are the implications for public health practice?Both MT-ZVL and imported cases showed an increasing trend in China. Therefore, two actions are needed to control VL: 1) to prevent re-emergence and spreading of MT-ZVL; and 2) to ensure timely diagnosis and appropriate treatment to avoid fatal VL cases, especially in non-endemic areas.
* Data include results of serological and fecal tests of local and floating populations in all surveillance sites throughout the country from 2015 to 2018 and all tests are standardized according to the requirements of the surveillance scheme.SLL: sero-prevalence of the local population in lake and marsh regions; SLW: sero-prevalence of the local population in water-network regions; SLM: sero-prevalence of the local population in mountainous regions; SPL: sero-prevalence of the local population; SPF: sero-prevalence of the floating population; EPL: estimated prevalence of the local population; EPF: estimated prevalence of the floating population.The estimated prevalence is equal to the fecal positive rate, which is the infection rate of Schistosoma in the population.
BACKGROUNDChina's growing prosperity has led to an increased role in international affairs, particularly in global health cooperation. Alongside sending medical teams abroad, China's health authority is gradually expanding its South-South cooperation in public health. However, due to a late start in global health initiatives and limited experience in organizing, coordinating, and implementing intervention projects overseas, China still faces significant challenges in global health, particularly in the local context. Recognizing the longstanding partnership between the Chinese and British governments, they have identified global health as a new area of strategic cooperation. In 2012, the former UK Department for International Development (DFID) initiated a new type of health development cooperation project named the China-UK Global Health Support Programme (GHSP).Malaria is a highly prevalent infectious disease that poses a significant threat to nearly half of the global population. The African Region of the World Health Organization (WHO) is especially susceptible, with approximately 95% of all malaria cases occurring in this region. Tanzania is among the four African countries that contribute to more than half of all malaria-related deaths, with a mortality rate of 4% (1). As a result, Tanzania faces substantial obstacles in the prevention and control of malaria. With the remarkable achievement in malaria control and elimination, China's extensive expertise in this field has played a pivotal role in shaping the basis of China-Africa collaboration.The China-UK-Tanzania Pilot Project on Malaria Control signifies China's inaugural endeavor in public health cooperation in Africa. This project represents a significant milestone in the adoption of China's "going global" approach, building on the initial outputs of the GHSP. The primary aim of the pilot project is to apply
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.